Literature DB >> 15898349

MK-431 (Merck).

Carolyn F Deacon1.   

Abstract

Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15898349

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  8 in total

1.  Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.

Authors:  Omprakash Tanwar; Girdhar Singh Deora; Lalima Tanwar; Gautam Kumar; Sridhara Janardhan; Mumtaz Alam; Mymoona Akhter
Journal:  J Mol Model       Date:  2014-04-01       Impact factor: 1.810

2.  Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.

Authors:  Leonor Corsino; Mary Elizabeth Cox; Jennifer Rowel; Jennifer B Green
Journal:  Clin Med Ther       Date:  2009-08-27

Review 3.  Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Authors:  J J Holst
Journal:  Diabetologia       Date:  2006-01-14       Impact factor: 10.122

4.  Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus.

Authors:  Erin L St Onge; Shannon Miller; Elizabeth Clements
Journal:  P T       Date:  2012-12

Review 5.  Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Clin Sci (Lond)       Date:  2007-08       Impact factor: 6.124

6.  Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.

Authors:  Mary Elizabeth Cox; Jennifer Rowell; Leonor Corsino; Jennifer B Green
Journal:  Drug Healthc Patient Saf       Date:  2010-01-28

Review 7.  Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

Authors:  B Richter; E Bandeira-Echtler; K Bergerhoff; C L Lerch
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

8.  Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile: a key intermediate for dipeptidyl peptidase IV inhibitors.

Authors:  Santosh Kumar Singh; Narendra Manne; Manojit Pal
Journal:  Beilstein J Org Chem       Date:  2008-06-12       Impact factor: 2.883
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.